Updated NETs Clinical Trials
Studies found on ClinicalTrials.gov by a search of: neuroendocrine NOT Melanoma NOT PMS | Recruiting, Not yet recruiting, Available Studies | Phase 2, 3, 4 | Last update posted in the last 30 days
-
Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer
Condition: Neuroendocrine Carcinomas
Interventions: Drug: Folfiri-bevacizumab; Drug: Folfiri
Sponsor: Hospices Civils de Lyon
Recruiting -
A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
Interventions: Drug: LEE011; Drug: everolimus
Sponsors: Memorial Sloan Kettering Cancer Center; Novartis; Dana-Farber Cancer Institute; M.D. Anderson Cancer Center
Recruiting -
Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
Conditions: Metastatic Large Cell Neuroendocrine Carcinoma; Metastatic Neuroendocrine Carcinoma; Metastatic Neuroendocrine Neoplasm; Metastatic Small Cell Carcinoma
Interventions: Drug: Cabozantinib; Drug: Cabozantinib S-malate; Biological: Ipilimumab; Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Not yet recruiting -
A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors
Condition: Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors
Interventions: Drug: AK105; Drug: Anlotinib
Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Not yet recruiting -
Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery
Conditions: Atypical Carcinoid Tumor; Carcinoid Tumor; Digestive System Neuroendocrine Neoplasm; Functioning Pancreatic Neuroendocrine Tumor; Intermediate Grade Lung Neuroendocrine Neoplasm; Low Grade Lung Neuroendocrine Neoplasm; Lung Atypical Carcinoid Tumor; Lung Carcinoid Tumor; Metastatic Digestive System Neuroendocrine Tumor G1; Neuroendocrine Neoplasm; Non-Functioning Pancreatic Neuroendocrine Tumor; Pancreatic Neuroendocrine Tumor; Serotonin-Producing Pancreatic Neuroendocrine Tumor; Stage IIIA Digestive System Neuroendocrine Tumor AJCC v7; Stage IIIB Digestive System Neuroendocrine Tumor AJCC v7; Stage IV Digestive System Neuroendocrine Tumor AJCC v7
Interventions: Drug: Cabozantinib S-malate; Other: Laboratory Biomarker Analysis; Other: Placebo Administration; Other: Quality-of-Life Assessment
Sponsor: National Cancer Institute (NCI)
Recruiting -
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
Conditions: Gastroenteropancreatico Tumors; Neuroendocrine Tumors; Neuroendocrine Neoplasms
Interventions: Drug: Lu-177-DOTATATE; Drug: Olaparib; Diagnostic Test: Ga dotatate scanning; Diagnostic Test: FDG-PET scanning
Sponsor: National Cancer Institute (NCI)
Not yet recruiting -
Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors
Condition: Gastroenteropancreatic Neuroendocrine Tumors
Interventions: Drug: Somatuline Depot; Drug: Keytruda
Sponsors: Duke University; Merck Sharp & Dohme Corp.; Ipsen
Recruiting -
Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases
Conditions: Liver Metastases; Colorectal Cancer; Anal Canal Cancer; Gastrointestinal Neuroendocrine Tumors
Intervention: Radiation: SBRT
Sponsors: University of Sao Paulo; Instituto do Cancer do Estado de São Paulo
Recruiting -
Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs
Condition: Neuroendocrine Tumors
Intervention: Drug: Satoreotide tetraxetan
Sponsor: Ipsen
Recruiting -
Cabozantinib and Nivolumab for Carcinoid Tumors
Conditions: Carcinoid Tumor; Carcinoid Tumor of GI System; Neuroendocrine Tumors
Interventions: Drug: Nivolumab; Drug: Cabozantinib
Sponsors: Dana-Farber Cancer Institute; Bristol-Myers Squibb; Exelixis
Recruiting -
Two Chemotherapy Regimens Plus or Minus Bevacizumab
Condition: Pancreatic Cancer
Interventions: Drug: LV5FU2; Drug: Streptozocin; Drug: Capecitabine; Drug: Temozolomide; Drug: Bevacizumab
Sponsors: Gustave Roussy, Cancer Campus, Grand Paris; National Cancer Institute, France
Recruiting -
Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
Condition: Gastro-enteropancreatic Neuroendocrine Tumor
Interventions: Drug: Lutathera; Drug: long-acting octreotide; Drug: high dose long-acting octreotide
Sponsor: Advanced Accelerator Applications
Not yet recruiting -
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Conditions: Acinar Cell Carcinoma; Adenoid Cystic Carcinoma; Adrenal Cortex Carcinoma; Adrenal Gland Pheochromocytoma; Anal Canal Neuroendocrine Carcinoma; Anal Canal Undifferentiated Carcinoma; Angiosarcoma; Apocrine Neoplasm; Appendix Mucinous Adenocarcinoma; Bartholin Gland Transitional Cell Carcinoma; Basal Cell Carcinoma; Bladder Adenocarcinoma; Cervical Adenocarcinoma; Cervical Clear Cell Adenocarcinoma; Cholangiocarcinoma; Chordoma; Colorectal Squamous Cell Carcinoma; Desmoid-Type Fibromatosis; Endometrial Transitional Cell Carcinoma; Endometrioid Adenocarcinoma; Esophageal Neuroendocrine Carcinoma; Esophageal Undifferentiated Carcinoma; Extrahepatic Bile Duct Carcinoma; Extramammary Paget Disease; Fallopian Tube Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fibromyxoid Tumor; Gallbladder Carcinoma; Gastric Neuroendocrine Carcinoma; Gastric Squamous Cell Carcinoma; Gastric Undifferentiated Carcinoma; Gastrointestinal Stromal Tumor; Gestational Trophoblastic Tumor; Giant Cell Carcinoma; Intestinal Neuroendocrine Carcinoma; Intrahepatic Cholangiocarcinoma; Lung Carcinoid Tumor; Lung Sarcomatoid Carcinoma; Major Salivary Gland Carcinoma; Malignant Odontogenic Neoplasm; Malignant Peripheral Nerve Sheath Tumor; Malignant Testicular Sex Cord-Stromal Tumor; Metaplastic Breast Carcinoma; Metastatic Malignant Neoplasm of Unknown Primary; Minimally Invasive Lung Adenocarcinoma; Mixed Mesodermal (Mullerian) Tumor; Mucinous Adenocarcinoma; Mucinous Cystadenocarcinoma; Nasal Cavity Adenocarcinoma; Nasal Cavity Carcinoma; Nasopharyngeal Carcinoma; Nasopharyngeal Papillary Adenocarcinoma; Nasopharyngeal Undifferentiated Carcinoma; Oral Cavity Carcinoma; Oropharyngeal Undifferentiated Carcinoma; Ovarian Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Germ Cell Tumor; Ovarian Mucinous Adenocarcinoma; Ovarian Squamous Cell Carcinoma; Ovarian Transitional Cell Carcinoma; Pancreatic Acinar Cell Carcinoma; Pancreatic Neuroendocrine Carcinoma; Paraganglioma; Paranasal Sinus Adenocarcinoma; Paranasal Sinus Carcinoma; Parathyroid Gland Carcinoma; PEComa; Peritoneal Mesothelioma; Pituitary Gland Carcinoma; Placental Choriocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Pseudomyxoma Peritonei; Rare Disorder; Scrotal Squamous Cell Carcinoma; Seminal Vesicle Adenocarcinoma; Seminoma; Serous Cystadenocarcinoma; Small Intestinal Adenocarcinoma; Small Intestinal Squamous Cell Carcinoma; Solid Neoplasm; Spindle Cell Neoplasm; Squamous Cell Carcinoma of the Penis; Teratoma With Somatic-Type Malignancy; Testicular Non-Seminomatous Germ Cell Tumor; Thyroid Gland Carcinoma; Tracheal Carcinoma; Transitional Cell Carcinoma; Ureter Adenocarcinoma; Ureter Squamous Cell Carcinoma; Urethral Adenocarcinoma; Urethral Squamous Cell Carcinoma; Vaginal Adenocarcinoma; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified; Vulvar Carcinoma
Interventions: Procedure: Biospecimen Collection; Biological: Ipilimumab; Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Recruiting -
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
Conditions: Pheochromocytoma; Paraganglioma; Neuroendocrine Tumors; Neuroendocrine Neoplasms
Interventions: Drug: Lu-177-DOTATATE; Drug: Ga-68-DOTATATE; Drug: F-18-FDG; Drug: Amino Acid solution
Sponsor: National Cancer Institute (NCI)
Recruiting -
Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.
Condition: Neoplasms
Interventions: Drug: Everolimus; Drug: Sandostatin LAR Depot
Sponsor: Novartis Pharmaceuticals
Recruiting -
Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide
Condition: SCLC, Extensive Stage
Intervention: Drug: Atezolizumab
Sponsors: AIO-Studien-gGmbH; Hoffmann-La Roche
Recruiting -
Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer
Conditions: KRAS Gene Mutation; Metastatic Colorectal Carcinoma; NRAS Gene Mutation; Stage III Colorectal Cancer AJCC v8; Stage IIIA Colorectal Neuroendocrine Tumor AJCC v8; Stage IIIB Colorectal Cancer AJCC v8; Stage IIIC Colorectal Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8; Unresectable Carcinoma
Interventions: Drug: Binimetinib; Drug: Palbociclib; Drug: Trifluridine and Tipiracil Hydrochloride
Sponsors: Academic and Community Cancer Research United; National Cancer Institute (NCI)
Recruiting -
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Conditions: Bladder Adenocarcinoma; Bladder Mixed Adenocarcinoma; Bladder Small Cell Carcinoma; Bladder Squamous Cell Carcinoma; Chromophobe Renal Cell Carcinoma; Infiltrating Bladder Lymphoepithelioma-Like Carcinoma; Infiltrating Bladder Urothelial Carcinoma; Infiltrating Bladder Urothelial Carcinoma With Giant Cells; Infiltrating Bladder Urothelial Carcinoma, Nested Variant; Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant; Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant; Kidney Medullary Carcinoma; Large Cell Neuroendocrine Carcinoma; Metastatic Bladder Carcinoma; Metastatic Bladder Large Cell Neuroendocrine Carcinoma; Metastatic Bladder Small Cell Carcinoma; Metastatic Bladder Squamous Cell Carcinoma; Metastatic Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant; Metastatic Infiltrating Bladder Urothelial Carcinoma, Lipid-Rich Variant; Metastatic Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant; Metastatic Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant; Metastatic Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant; Metastatic Kidney Medullary Carcinoma; Metastatic Malignant Genitourinary System Neoplasm; Metastatic Penile Carcinoma; Metastatic Prostate Small Cell Carcinoma; Metastatic Sarcomatoid Renal Cell Carcinoma; Papillary Renal Cell Carcinoma; Sarcomatoid Renal Cell Carcinoma; Stage IV Bladder Cancer AJCC v8; Stage IV Penile Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Stage IVA Bladder Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Bladder Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8; Testicular Leydig Cell Tumor; Testicular Sertoli Cell Tumor
Interventions: Drug: Cabozantinib; Drug: Cabozantinib S-malate; Biological: Ipilimumab; Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Recruiting -
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
Conditions: RET-altered Non Small Cell Lung Cancer; Medullary Thyroid Cancer; RET-altered Papillary Thyroid Cancer; RET-altered Colon Cancer; RET-altered Solid Tumors; Lung Neoplasm; Carcinoma, Non-Small-Cell Lung; Thyroid Diseases; Thyroid Neoplasm; Thyroid Cancer, Papillary; Carcinoma, Neuroendocrine; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Disease; Carcinoma, Bronchogenic; Bronchial Neoplasms; Endocrine System Diseases; Endocrine Gland Neoplasm; Head and Neck Neoplasms; Adenocarcinoma, Papillary; Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neuroendocrine Tumors; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Colonic Neoplasms; Colorectal Neoplasms; Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasm; Digestive System Disease; Gastrointestinal Disease; Colonic Diseases; Intestinal Disease
Intervention: Drug: pralsetinib (BLU-667)
Sponsor: Blueprint Medicines Corporation
Recruiting -
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
Condition: Medullary Thyroid Cancer
Interventions: Drug: Selpercatinib; Drug: Cabozantinib; Drug: Vandetanib
Sponsors: Eli Lilly and Company; Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company
Not yet recruiting -
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers
Conditions: Carcinoma, Non-Small -Cell Lung; Ovarian Neoplasms; Small Cell Lung Carcinoma; Uterine Cervical Neoplasms; Carcinoma, Neuroendocrine; Extrapulmonary Small Cell Cancer
Interventions: Drug: Topotecan; Drug: VX-970 (M6620)
Sponsor: National Cancer Institute (NCI)
Recruiting -
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Conditions: Locally Advanced Solid Tumors; Metastatic Solid Tumors
Intervention: Drug: Oral repotrectinib (TPX-0005)
Sponsor: Turning Point Therapeutics, Inc.
Recruiting -
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Condition: Advanced Cancer
Intervention: Biological: pembrolizumab
Sponsor: Merck Sharp & Dohme Corp.
Recruiting -
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Conditions: Adrenal Cortex Carcinoma; Alveolar Soft Part Sarcoma; Central Nervous System Neoplasm; Childhood Clear Cell Sarcoma of Soft Parts; Clear Cell Sarcoma of Soft Tissue; Ewing Sarcoma; Hepatoblastoma; Hepatocellular Carcinoma; Osteosarcoma; Recurrent Adrenal Cortex Carcinoma; Recurrent Alveolar Soft Part Sarcoma; Recurrent Ewing Sarcoma; Recurrent Hepatoblastoma; Recurrent Hepatocellular Carcinoma; Recurrent Malignant Central Nervous System Neoplasm; Recurrent Malignant Solid Neoplasm; Recurrent Osteosarcoma; Recurrent Renal Cell Carcinoma; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Recurrent Thyroid Gland Medullary Carcinoma; Refractory Ewing Sarcoma; Refractory Malignant Central Nervous System Neoplasm; Refractory Malignant Solid Neoplasm; Refractory Osteosarcoma; Refractory Rhabdomyosarcoma; Refractory Soft Tissue Sarcoma; Renal Cell Carcinoma; Rhabdomyosarcoma; Solid Neoplasm; Thyroid Gland Medullary Carcinoma; Wilms Tumor
Interventions: Drug: Cabozantinib; Drug: Cabozantinib S-malate; Other: Pharmacological Study
Sponsor: National Cancer Institute (NCI)
Recruiting -
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutation With Advanced Breast Cancer Who Have Progressed on or After Prior Treatments
Condition: Breast Cancer
Interventions: Drug: alpelisib; Drug: fulvestrant; Drug: letrozole; Drug: Goserelin; Drug: Leuprolide
Sponsor: Novartis Pharmaceuticals
Recruiting -
Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699
Condition: Cushing's Syndrome
Intervention: Drug: osilodrostat
Sponsor: Novartis Pharmaceuticals
Recruiting -
This Study Evaluates KRT-232, a Novel Oral Small Molecule Inhibitor of MDM2, for the Treatment of Patients With (p53WT) Merkel Cell Carcinoma Who Have Failed Anti-PD-1/ PD-L1 Immunotherapy
Condition: Merkel Cell Carcinoma
Intervention: Drug: KRT-232
Sponsor: Kartos Therapeutics, Inc.
Recruiting -
Pembrolizumab Compared to Standard of Care Observation in Treating Patients With Completely Resected Stage I-III Merkel Cell Cancer
Conditions: Pathologic Stage I Merkel Cell Carcinoma AJCC v8; Pathologic Stage II Merkel Cell Carcinoma AJCC v8; Pathologic Stage IIA Merkel Cell Carcinoma AJCC v8; Pathologic Stage IIB Merkel Cell Carcinoma AJCC v8; Pathologic Stage III Merkel Cell Carcinoma AJCC v8; Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8; Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8
Interventions: Other: Best Practice; Biological: Pembrolizumab; Radiation: Radiation Therapy
Sponsor: National Cancer Institute (NCI)
Recruiting -
A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)
Condition: Metastatic Merkel Cell Carcinoma
Intervention: Drug: INCMGA00012
Sponsor: Incyte Corporation
Recruiting -
Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
Conditions: Metastatic Kidney Medullary Carcinoma; Metastatic Renal Cell Carcinoma; SMARCB1 Negative; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8
Interventions: Drug: Doxorubicin; Drug: Doxorubicin Hydrochloride; Drug: Gemcitabine; Drug: Gemcitabine Hydrochloride; Drug: Ixazomib; Drug: Ixazomib Citrate
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting -
Adjuvant Avelumab in Merkel Cell Cancer
Conditions: Stage III Merkel Cell Carcinoma AJCC v7; Stage IIIB Merkel Cell Carcinoma AJCC v7
Interventions: Drug: Avelumab; Other: Laboratory Biomarker Analysis; Other: Placebo
Sponsors: University of Washington; National Cancer Institute (NCI); EMD Serono
Recruiting -
A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer
Conditions: Paraganglioma; Gastrointestinal Stromal Tumors; Carcinoma, Renal Cell; Renal Neoplasms; Pheochromocytoma
Intervention: Drug: SGI-110 (guadecitabine)
Sponsor: National Cancer Institute (NCI)
Recruiting